Literature DB >> 23408180

Craniocervical decompression in patients with mucopolysaccharidosis VI: development of a scoring system to determine indication and outcome of surgery.

Christina Lampe1, Christian Lampe, Manfred Schwarz, Wibke Müller-Forell, Paul Harmatz, Eugen Mengel.   

Abstract

OBJECTIVE: To analyse diagnostic value of somato-sensory evoked potentials (SEP), magnetic resonance imaging (MRI), and clinical neurological examination in the decision for decompression surgery in mucopolysaccharidosis (MPS) VI patients with craniocervical cord compression (CCJ).
METHODS: We retrospectively analysed neurological examination, SEP of the median nerve and MRI outcomes from 31 MPS VI patients. Individual scores for each test (based on severity of findings) and a sum of scores of all three procedures (CCJ score) were evaluated for their potential to measure the need for and improvement after surgery. Differences between rapidly and slowly progressive patients were also evaluated.
RESULTS: Fourteen patients (45 %) aged 4-34 years underwent decompression surgery. Median age at first operation was lower in rapidly than in slowly progressive patients (12 vs. 24 years; P = 0.008). Neurological and SEP findings but not MRI results differed significantly between non-operated and operated patients (P < 0.001, P = 0.003 and P = 0.08, respectively). A significant relationship was found between MRI and clinical neurological examination (P < 0.001) and between SEP and clinical neurological examination (P = 0.01) but not between MRI and SEP (P = 0.06). The CCJ score discriminated between operated and non-operated patients (4-9 points vs. 0-3 points; P < 0.001) and decreased in 61.5 % of patients after surgery.
CONCLUSIONS: CCJ is common in rapidly and slowly progressive MPS VI patients. The CCJ score is an objective and transparent tool for assessing pathology of the CCJ, the need for surgery, and improvement after surgery.

Entities:  

Mesh:

Year:  2013        PMID: 23408180     DOI: 10.1007/s10545-013-9591-5

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  16 in total

Review 1.  Management guidelines for mucopolysaccharidosis VI.

Authors:  Roberto Giugliani; Paul Harmatz; James E Wraith
Journal:  Pediatrics       Date:  2007-08       Impact factor: 7.124

Review 2.  Multilevel myelopathy in Maroteaux-Lamy syndrome and review of the literature.

Authors:  Melike Mut; Ayşenur Cila; Kubilay Varli; Nejat Akalan
Journal:  Clin Neurol Neurosurg       Date:  2005-04       Impact factor: 1.876

3.  Craniovertebral abnormalities in Type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome).

Authors:  J A Thorne; M Javadpour; D G Hughes; E Wraith; R A Cowie
Journal:  Neurosurgery       Date:  2001-04       Impact factor: 4.654

4.  Myelopathy due to diffuse thickening of the cervical dura mater in Maroteaux-Lamy syndrome: report of a case.

Authors:  N Tamaki; N Kojima; M Tanimoto; T Suyama; S Matsumoto
Journal:  Neurosurgery       Date:  1987-09       Impact factor: 4.654

Review 5.  Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation.

Authors:  E Kachur; R Del Maestro
Journal:  Neurosurgery       Date:  2000-07       Impact factor: 4.654

6.  Subcortical somatosensory evoked potentials after median nerve stimulation in children.

Authors:  R Boor; B Goebel; M J Taylor
Journal:  Eur J Paediatr Neurol       Date:  1998       Impact factor: 3.140

7.  Abnormal somatosensory evoked potentials indicate compressive cervical myelopathy in mucopolysaccharidoses.

Authors:  R Boor; E Miebach; K Brühl; M Beck
Journal:  Neuropediatrics       Date:  2000-06       Impact factor: 1.947

8.  Urinary glycosaminoglycan excretion in healthy subjects and in patients with mucopolysaccharidoses.

Authors:  M P Gallegos-Arreola; M V Machorro-Lazo; S E Flores-Martínez; G M Zúñiga-González; L E Figuera; A González-Noriega; J Sánchez-Corona
Journal:  Arch Med Res       Date:  2000 Sep-Oct       Impact factor: 2.235

9.  Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

Authors:  Stuart J Swiedler; Michael Beck; Manal Bajbouj; Roberto Giugliani; Ida Schwartz; Paul Harmatz; James E Wraith; Jane Roberts; David Ketteridge; John J Hopwood; Nathalie Guffon; M Clara Sá Miranda; Elisa Leão Teles; Kenneth I Berger; Cheri Piscia-Nichols
Journal:  Am J Med Genet A       Date:  2005-04-15       Impact factor: 2.802

Review 10.  Mucopolysaccharidosis VI.

Authors:  Vassili Valayannopoulos; Helen Nicely; Paul Harmatz; Sean Turbeville
Journal:  Orphanet J Rare Dis       Date:  2010-04-12       Impact factor: 4.123

View more
  7 in total

1.  Spinal cord issues in adult patients with MPS: transition of care survey.

Authors:  Kemel A Ghotme; Fernando Alvarado-Gomez; Christina Lampe; Klane K White; Martha Solano-Villareal; Roberto Giugliani; Paul R Harmatz
Journal:  Childs Nerv Syst       Date:  2018-05-27       Impact factor: 1.475

2.  Clinical Evolution After Enzyme Replacement Therapy in Twins with the Severe Form of Maroteaux-Lamy Syndrome.

Authors:  M Pineda; M O'Callaghan; A Fernandez Lopez; M J Coll; R Ullot; G Garcia-Fructuoso
Journal:  JIMD Rep       Date:  2016-02-27

3.  Evaluation of spinal involvement in children with mucopolysaccharidosis VI: the role of MRI.

Authors:  Elif Bulut; Emine Pektas; Hatice S Sivri; Burcak Bilginer; Mumtaz M Umaroglu; Burce Ozgen
Journal:  Br J Radiol       Date:  2018-02-13       Impact factor: 3.039

4.  Musculoskeletal manifestations in mucopolysaccharidosis type I (Hurler syndrome) following hematopoietic stem cell transplantation.

Authors:  Mona Schmidt; Sandra Breyer; Ulrike Löbel; Sinef Yarar; Ralf Stücker; Kurt Ullrich; Ingo Müller; Nicole Muschol
Journal:  Orphanet J Rare Dis       Date:  2016-07-08       Impact factor: 4.123

5.  Correlation of CSF flow using phase-contrast MRI with ventriculomegaly and CSF opening pressure in mucopolysaccharidoses.

Authors:  Amauri Dalla Corte; Carolina F M de Souza; Maurício Anés; Fabio K Maeda; Armelle Lokossou; Leonardo M Vedolin; Maria Gabriela Longo; Monica M Ferreira; Solanger G P Perrone; Olivier Balédent; Roberto Giugliani
Journal:  Fluids Barriers CNS       Date:  2017-09-18

Review 6.  Diagnostic and treatment strategies in mucopolysaccharidosis VI.

Authors:  Filippo Vairo; Andressa Federhen; Guilherme Baldo; Mariluce Riegel; Maira Burin; Sandra Leistner-Segal; Roberto Giugliani
Journal:  Appl Clin Genet       Date:  2015-10-30

Review 7.  Non-cardiac Manifestations in Adult Patients With Mucopolysaccharidosis.

Authors:  Karolina M Stepien; Andrew Bentley; Cliff Chen; M Wahab Dhemech; Edward Gee; Peter Orton; Catherine Pringle; Jonathan Rajan; Ankur Saxena; Govind Tol; Chaitanya Gadepalli
Journal:  Front Cardiovasc Med       Date:  2022-03-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.